Study on value-based medical insurance access and pricing methods of multi-indication drugs
- VernacularTitle:基于价值的多适应证药品医保准入与定价方法研究
- Author:
Yingcheng WANG
1
,
2
;
Yao WU
1
,
2
;
Lan YANG
1
,
2
;
Mingjun RUI
1
,
2
;
Hongchao LI
1
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Pharmacoeconomics Evaluation Research Center，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
multi-indication drugs;
value-based pricing;
pricing methods;
medical insurance access
- From:
China Pharmacy
2023;34(2):179-184
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To discuss medical insurance access and pricing methods for multi-indication drugs. METHODS The access situation of multi-indication drugs in China’s medical insurance negotiation over the years was sorted out. Referring to the economic theory of value-based pricing and the relevant experience of other countries， five applicable pricing methods of 3 categories for multi-indication drug in China were summarized. Taking ceftazidime-avibactam（CAZ-AVI） as an example， cost- utility analyses were performed for different indications， and appropriate pricing methods were applied. RESULTS & CONCLUSIONS All multi-indication drugs in China adopted a single pricing method. The pricing methods that could be explored include product-based pricing， such as single pricing based on the lower-value indication or mixed/weighted single pricing； indication-based pricing， such as developing a new agreement for single pricing under different discounts and listing with different brands and pricing of the same medicine for different indications； and compensation for access restrictions. Each method has its advantages and limitations. The case of CAZ-AVI showed that it is necessary to estimate the value of each indication for multi- indication drugs， and comprehensively consider appropriate access conditions and pricing methods based on value. Although single pricing is simple to operate， it is different to reflect the value entirely. The indication-based pricing and compensation for access restrictions all depend on the information collection system and the cooperation of multiple departments. China is supposed to carry out the value-based pricing of multi-indication drugs and constantly explore reasonable access methods to improve overall social welfare.
